Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Simvastatin (02269252), PMS-Simvastatin (02269260), PMS-Simvastatin (02269279), PMS-Simvastatin (02269287), PMS-Simvastatin (02269295). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
SIMVASTATIN
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C10A, C10AA) — coverage varies; not interchangeable
- Atorvastatin (Lipitor): general benefit
- Fluvastatin (Lescol): general benefit, Not a benefit
- Lovastatin (Mevacor): general benefit, Not a benefit
- Pravastatin (Pravachol): general benefit, Not a benefit
- Rosuvastatin (Crestor): general benefit
- Bezafibrate (Bezalip): general benefit
9 more in the class list below
Apo-Simvastatin · DIN 02247011 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Simvastatin · DIN 02247011
Manufacturer: Apotex Inc.; listing date 2003-04-16
Health Canada: Marketed since 2002-12-20 · brand APO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Apotex inc · schedule Prescription
Apo-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71245 · Verify on the e-Formulary ↗ (DIN 02247011)
Source record
DIN 02247011: Apo-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247011
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71245
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2018-11-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247011
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Simvastatin · DIN 02405148 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Simvastatin · DIN 02405148
Manufacturer: Auro Pharma Inc.; listing date 2013-09-27
Health Canada: Marketed since 2013-07-08 · brand AURO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Auro pharma inc · schedule Prescription
Auro-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88996 · Verify on the e-Formulary ↗ (DIN 02405148)
Source record
DIN 02405148: Auro-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405148
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88996
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405148
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Simvastatin · DIN 02375591 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Simvastatin · DIN 02375591
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Marketed since 2018-10-16 · brand JAMP-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86101 · Verify on the e-Formulary ↗ (DIN 02375591)
Source record
DIN 02375591: Jamp-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375591
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86101
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: active shortage (reported 2025-10-31, estimated to end 2026-12-25, last updated 2026-07-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375591
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Simvastatin · DIN 02372932 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Simvastatin · DIN 02372932
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2011-12-15
Health Canada: Marketed since 2011-09-07 · brand MINT-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85804 · Verify on the e-Formulary ↗ (DIN 02372932)
Source record
DIN 02372932: Mint-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372932
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85804
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2019-11-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372932
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMSC-Simvastatin · DIN 02549638 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMSC-Simvastatin · DIN 02549638
Manufacturer: Pharmascience Inc.; listing date 2025-07-31
Health Canada: Marketed since 2025-05-30 · brand PMSC-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Pharmascience inc · schedule Prescription
PMSC-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103845 · Verify on the e-Formulary ↗ (DIN 02549638)
Source record
DIN 02549638: PMSC-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549638
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103845
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549638
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pharma-Simvastatin · DIN 02469979 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pharma-Simvastatin · DIN 02469979
Manufacturer: Pharmascience Inc.; listing date 2018-07-31
Health Canada: Marketed since 2017-11-29 · brand PHARMA-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Pharmascience inc · schedule Prescription
Pharma-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95892 · Verify on the e-Formulary ↗ (DIN 02469979)
Source record
DIN 02469979: Pharma-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469979
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95892
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2023-02-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469979
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Simvastatin · DIN 02329131 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Simvastatin · DIN 02329131
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-11-13
Health Canada: Marketed since 2020-01-20 · brand TARO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Sun pharma canada inc · schedule Prescription
Ran-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81483 · Verify on the e-Formulary ↗ (DIN 02329131)
Source record
DIN 02329131: Ran-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id RAN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02329131
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81483
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2022-10-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02329131
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Simvastatin · DIN 02284723 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Simvastatin · DIN 02284723
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2021-03-03 · brand SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Sanis health inc · schedule Prescription
Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77028 · Verify on the e-Formulary ↗ (DIN 02284723)
Source record
DIN 02284723: Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284723
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77028
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: active shortage (reported 2026-07-15, estimated to end 2026-11-13, last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284723
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Simvastatin · DIN 02386291 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Simvastatin · DIN 02386291
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-07-29
Health Canada: Marketed since 2022-05-31 · brand SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87187 · Verify on the e-Formulary ↗ (DIN 02386291)
Source record
DIN 02386291: Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386291
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87187
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Teva-Simvastatin · DIN 02250144 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: resolved shortage (ended 2022-06-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386291
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Simvastatin · DIN 02250144 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Simvastatin · DIN 02250144
Manufacturer: Teva Canada Limited; listing date 2004-07-20
Health Canada: Marketed since 2010-05-01 · brand TEVA-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 5 MG · company Teva canada limited · schedule Prescription
Teva-Simvastatin: Formulary list price $0.1023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73495 · Verify on the e-Formulary ↗ (DIN 02250144)
Source record
DIN 02250144: Teva-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600017; group id 309; item number 0678; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1023; ministry $0.1023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250144
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73495
Interchangeable products
AG-Simvastatin · DIN 02480050 · $0.1023
Apo-Simvastatin · DIN 02247011 · $0.1023
Auro-Simvastatin · DIN 02405148 · $0.1023
Co Simvastatin · DIN 02248103 · $0.1023
Jamp-Simvastatin · DIN 02375591 · $0.1023
Mar-Simvastatin · DIN 02375036 · $0.1023
Mint-Simvastatin · DIN 02372932 · $0.1023
PMSC-Simvastatin · DIN 02549638 · $0.1023
Pharma-Simvastatin · DIN 02469979 · $0.1023
Ran-Simvastatin · DIN 02329131 · $0.1023
Simvastatin · DIN 02284723 · $0.1023
Simvastatin · DIN 02386291 · $0.1023
Zocor · DIN 00884324 · not recorded
Shortage status: active shortage (reported 2026-04-30, estimated to end 2026-08-31, last updated 2026-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02250144
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Simvastatin · DIN 02247012 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Simvastatin · DIN 02247012
Manufacturer: Apotex Inc.; listing date 2003-04-16
Health Canada: Marketed since 2002-12-20 · brand APO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Apotex inc · schedule Prescription
Apo-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71246 · Verify on the e-Formulary ↗ (DIN 02247012)
Source record
DIN 02247012: Apo-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247012
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71246
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2023-11-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247012
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Simvastatin · DIN 02405156 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Simvastatin · DIN 02405156
Manufacturer: Auro Pharma Inc.; listing date 2013-09-27
Health Canada: Marketed since 2013-07-08 · brand AURO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Auro pharma inc · schedule Prescription
Auro-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88998 · Verify on the e-Formulary ↗ (DIN 02405156)
Source record
DIN 02405156: Auro-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405156
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88998
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2024-04-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405156
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Simvastatin · DIN 02375605 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Simvastatin · DIN 02375605
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Marketed since 2018-10-17 · brand JAMP-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86102 · Verify on the e-Formulary ↗ (DIN 02375605)
Source record
DIN 02375605: Jamp-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375605
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86102
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2022-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375605
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Simvastatin · DIN 02375044 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Simvastatin · DIN 02375044
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Health Canada: Marketed since 2012-12-20 · brand MAR-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86044 · Verify on the e-Formulary ↗ (DIN 02375044)
Source record
DIN 02375044: Mar-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375044
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86044
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: active shortage (reported 2018-05-02, last updated 2018-10-30) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375044
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Simvastatin · DIN 02372940 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Simvastatin · DIN 02372940
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2011-12-15
Health Canada: Marketed since 2011-09-07 · brand MINT-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85805 · Verify on the e-Formulary ↗ (DIN 02372940)
Source record
DIN 02372940: Mint-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id MIN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02372940
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85805
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372940
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMSC-Simvastatin · DIN 02549646 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMSC-Simvastatin · DIN 02549646
Manufacturer: Pharmascience Inc.; listing date 2025-07-31
Health Canada: Marketed since 2025-05-30 · brand PMSC-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Pharmascience inc · schedule Prescription
PMSC-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103846 · Verify on the e-Formulary ↗ (DIN 02549646)
Source record
DIN 02549646: PMSC-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549646
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103846
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549646
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pharma-Simvastatin · DIN 02469987 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Pharma-Simvastatin · DIN 02469987
Manufacturer: Pharmascience Inc.; listing date 2018-04-30
Health Canada: Marketed since 2017-11-29 · brand PHARMA-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Pharmascience inc · schedule Prescription
Pharma-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95893 · Verify on the e-Formulary ↗ (DIN 02469987)
Source record
DIN 02469987: Pharma-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469987
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95893
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2023-01-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02469987
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Simvastatin · DIN 02329158 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Simvastatin · DIN 02329158
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2009-11-13
Health Canada: Marketed since 2020-01-20 · brand TARO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Sun pharma canada inc · schedule Prescription
Ran-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81484 · Verify on the e-Formulary ↗ (DIN 02329158)
Source record
DIN 02329158: Ran-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02329158
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81484
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2026-01-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02329158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Simvastatin · DIN 02284731 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Simvastatin · DIN 02284731
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2021-03-03 · brand SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Sanis health inc · schedule Prescription
Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77029 · Verify on the e-Formulary ↗ (DIN 02284731)
Source record
DIN 02284731: Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284731
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77029
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2021-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284731
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Simvastatin · DIN 02386305 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Simvastatin · DIN 02386305
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-07-29
Health Canada: Marketed since 2022-05-31 · brand SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87188 · Verify on the e-Formulary ↗ (DIN 02386305)
Source record
DIN 02386305: Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386305
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87188
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2022-07-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386305
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Simvastatin · DIN 02250152 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Simvastatin · DIN 02250152
Manufacturer: Teva Canada Limited; listing date 2004-07-20
Health Canada: Marketed since 2010-05-01 · brand TEVA-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Teva canada limited · schedule Prescription
Teva-Simvastatin: Formulary list price $0.2023/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73496 · Verify on the e-Formulary ↗ (DIN 02250152)
Source record
DIN 02250152: Teva-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2023; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250152
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73496
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Zocor · DIN 00884332 · $0.2023
Shortage status: resolved shortage (ended 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02250152
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Zocor · DIN 00884332 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Zocor (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Zocor · DIN 00884332
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2022-03-11 · brand ZOCOR · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 10 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $0.2023 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10947 · Verify on the e-Formulary ↗ (DIN 00884332)
Source record
DIN 00884332: Zocor
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600016; group id 309; item number 0679; lccId None; manufacturer id OCI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.8190; ministry $0.2023
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00884332
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10947
Interchangeable products
AG-Simvastatin · DIN 02480069 · $0.2023
Apo-Simvastatin · DIN 02247012 · $0.2023
Auro-Simvastatin · DIN 02405156 · $0.2023
Co Simvastatin · DIN 02248104 · $0.2023
Jamp-Simvastatin · DIN 02375605 · $0.2023
Mar-Simvastatin · DIN 02375044 · $0.2023
Mint-Simvastatin · DIN 02372940 · $0.2023
PMSC-Simvastatin · DIN 02549646 · $0.2023
Pharma-Simvastatin · DIN 02469987 · $0.2023
Ran-Simvastatin · DIN 02329158 · $0.2023
Simvastatin · DIN 02284731 · $0.2023
Simvastatin · DIN 02386305 · $0.2023
Taro-Simvastatin · DIN 02265885 · not recorded
Teva-Simvastatin · DIN 02250152 · $0.2023
Shortage status: resolved shortage (ended 2024-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00884332
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Simvastatin · DIN 02247013 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Simvastatin · DIN 02247013
Manufacturer: Apotex Inc.; listing date 2003-04-16
Health Canada: Marketed since 2002-12-20 · brand APO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 20 MG · company Apotex inc · schedule Prescription
Apo-Simvastatin: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2501 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71247 · Verify on the e-Formulary ↗ (DIN 02247013)
Source record
DIN 02247013: Apo-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600028; group id 309; item number 0680; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2501; ministry $0.2501
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247013
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71247
Interchangeable products
AG-Simvastatin · DIN 02480077 · $0.2501
Auro-Simvastatin · DIN 02405164 · $0.2501
Co Simvastatin · DIN 02248105 · $0.2501
Jamp-Simvastatin · DIN 02375613 · $0.2501
Mar-Simvastatin · DIN 02375052 · $0.2501
Mint-Simvastatin · DIN 02372959 · $0.2501
PMSC-Simvastatin · DIN 02549654 · $0.2501
Pharma-Simvastatin · DIN 02469995 · $0.2501
Ran-Simvastatin · DIN 02329166 · $0.2501
Simvastatin · DIN 02284758 · $0.2501
Simvastatin · DIN 02386313 · $0.2501
Taro-Simvastatin · DIN 02265893 · not recorded
Teva-Simvastatin · DIN 02250160 · $0.2501
Zocor · DIN 00884340 · $0.2501
Shortage status: resolved shortage (ended 2022-04-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247013
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Simvastatin · DIN 02405164 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Simvastatin · DIN 02405164
Manufacturer: Auro Pharma Inc.; listing date 2013-09-27
Health Canada: Marketed since 2013-07-08 · brand AURO-SIMVASTATIN · ATC C10AA01 SIMVASTATIN · form Tablet · route Oral · ingredients SIMVASTATIN 20 MG · company Auro pharma inc · schedule Prescription
Auro-Simvastatin: Formulary list price $0.2501/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2501 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88999 · Verify on the e-Formulary ↗ (DIN 02405164)
Source record
DIN 02405164: Auro-Simvastatin
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240600028; group id 309; item number 0680; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2501; ministry $0.2501
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02405164
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88999
Interchangeable products
AG-Simvastatin · DIN 02480077 · $0.2501
Apo-Simvastatin · DIN 02247013 · $0.2501
Co Simvastatin · DIN 02248105 · $0.2501
Jamp-Simvastatin · DIN 02375613 · $0.2501
Mar-Simvastatin · DIN 02375052 · $0.2501
Mint-Simvastatin · DIN 02372959 · $0.2501
PMSC-Simvastatin · DIN 02549654 · $0.2501
Pharma-Simvastatin · DIN 02469995 · $0.2501
Ran-Simvastatin · DIN 02329166 · $0.2501
Simvastatin · DIN 02284758 · $0.2501
Simvastatin · DIN 02386313 · $0.2501
Taro-Simvastatin · DIN 02265893 · not recorded
Teva-Simvastatin · DIN 02250160 · $0.2501
Zocor · DIN 00884340 · $0.2501
Shortage status: resolved shortage (ended 2024-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02405164
Shortage record checked 2026-09-13T08:10:21.292534+00:00